The Analysis Of Final And Surrogate Effectiveness Criteria Used In Health Economic Studies Of Drugs Submitted Into The Reimbursement In Russia In 2016
OBJECTIVES: It is known that different outcomes used in health-economic studies make the comparative effectiveness and calculation of the cost of additional effectiveness complicated. The share of final outcomes used in health-economic evaluations is still unknown. OBJECTIVES. To evaluate the endpoi...
Gespeichert in:
Veröffentlicht in: | Value in health 2017-10, Vol.20 (9), p.A678 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | OBJECTIVES: It is known that different outcomes used in health-economic studies make the comparative effectiveness and calculation of the cost of additional effectiveness complicated. The share of final outcomes used in health-economic evaluations is still unknown. OBJECTIVES. To evaluate the endpoints (final or surrogate) used in health economic studies submitted for inclusion into the reimbursement in Russia in 2016. METHODS: We used the health economic studies submitted in drug dossiers in accordance with the Governmental decree N»871. We took into the database from each of the health economic study following parameters: the number of outcomes, the number of final and surrogate endpoints. RESULTS: We counted 161 outcomes in 138 health economic studies, 83 outcomes (52%) are final endpoints, 71 (52%) from 138 health economic studies have no final endpoints. The highest share of final endpoints was seen among the drugs with L01 ATC code - antineoplastic agents. The number of final endpoints was 75% and 63% in the group of drugs used in T2DM and CAD. The high total number of outcomes (submitted dossiers) was seen in the groups of drugs used for chronic hepatitis, asthma and COPD, rheumatic diseases but the share of final endpoints in these drug groups are low: 50%, 38% and 14%, consequently. We mentioned the absence of final endpoints in the drug groups used for arterial hypertension and benign prostate hyperplasia. CONCLUSIONS: 1). 52% of the total outcomes in the health economic studies submitted with the drug dossiers in 2016 have final endpoints. 2). The highest final endpoints share (80%) was seen in the group of antineoplastic drugs. 3). The low final endpoints share ( |
---|---|
ISSN: | 1098-3015 1524-4733 |
DOI: | 10.1016/j.jval.2017.08.1683 |